Survival is not a good outcome for randomized trials with effective subsequent therapies

Journal of Clinical Oncology

Volumn 29, Issue 35, 2011, Pages 4719-4720

  Buyse, Marc ^a   Sargent, Daniel J ^b   Saad, Everardo D ^c  

^a INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^b MAYO CLINIC   (United States)

^c Dendrix Research   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; EXPERIMENTAL THERAPY; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME;

HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 83255164843     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.4206     Document Type: Letter

References (6)

1. Korn EL, Freidlin B, Abrams JS: Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 29:2439-2442, 2011
2. Sargent DJ, Hayes DF: Assessing the measure of a new drug: Is survival the only thing that matters? J Clin Oncol 26:1922-1923, 2008
3. D'Agostino RB Sr: Changing end points in breast-cancer drug approval: The Avastin story. N Engl J Med 365:e2, 2011
4. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al.: Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987-1992, 2008
5. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649, 2009
6. Saad ED, Katz A, Buyse M: Overall survival and post-progression survival in advanced breast cancer: A review of recent randomized clinical trials. J Clin Oncol 28:1958-1962, 2010